Dr. Danny Benjamin joins me again to discuss COVID19 delta variant in children, vaccines and the critical research that his team performed regarding back to school in North Carolina. He is the Kiser Arena Distinguished Professor of Pediatrics at Duke University and the Principle Investigator of the National Institute of Child Health and Human Development Pediatric Trials Network. His group performed two large trials of children going back to school in 2020 effectively proving that children being in school face to face was and is safe. We discuss the safety of the mRNA vaccines in the 5 to 12 year old age group.
Enjoy my conversation with Dr. Danny Benjamin,
Coronavirus Updates #44 and 45 – Listen to the latest data driven perspectives on the pandemic. Vaccine boosters, MIS and what is happening now are covered. For the written versions please visit: https://www.salisburypediatrics.com/patient-education/dr-magryta-s-newsletter
A few people are asking about the need to vaccinate if you have already had COVID natural illness. What is the story here? Hot off of the press from Cell Reports Medicine, we see: “Ending the COVID-19 pandemic will require long-lived immunity to SARS-CoV-2. Here, we evaluate 254 COVID-19 patients longitudinally up to 8 months and find durable broad-based immune responses. SARS-CoV-2 spike binding and neutralizing antibodies exhibit a bi-phasic decay with an extended half-life of >200 days suggesting the generation of longer-lived plasma cells. SARS-CoV-2 infection also boosts antibody titers to SARS-CoV-1 and common betacoronaviruses. In addition, spike-specific IgG+ memory B cells persist, which bodes well for a rapid antibody response upon virus re-exposure or vaccination. Virus-specific CD4+ and CD8+ T cells are polyfunctional and maintained with an estimated half-life of 200 days. Interestingly, CD4+ T cell responses equally target several SARS-CoV-2 proteins, whereas the CD8+ T cell responses preferentially target the nucleoprotein, highlighting the potential importance of including the nucleoprotein in future vaccines. Taken together, these results suggest that broad and effective immunity may persist long-term in recovered COVID-19 patients.” (Cohen et. al. 2021)
Read more for COVID #41……https://www.salisburypediatrics.com/patient-education/dr-magryta-s-newsletter/988-volume-11-letter-33-coronavirus-update-42
Read more for COVID #42……https://www.salisburypediatrics.com/patient-education/dr-magryta-s-newsletter/994-coronavirus-update-42
What are the latest data trends with COVID and children? What vaccine related issues have arisen? We answer these questions and more!
1) Sequelae following a moderate to severe COVID infection continue to plague medical systems. In a new study in the British Medical Journal, we see a 14% increased risk of developing new onset clinical conditions.
“14% of adults aged ≤65 who were infected with SARS-CoV-2 (27 074 of 193 113) had at least one new type of clinical sequelae that required medical care after the acute phase of the illness, which was 4.95% higher than in the 2020 comparator group. The risk for specific new sequelae attributable to SARS-Cov-2 infection after the acute phase, including chronic respiratory failure, cardiac arrythmia, hypercoagulability, encephalopathy, peripheral neuropathy, amnesia (memory difficulty), diabetes, liver test abnormalities, myocarditis, anxiety, and fatigue, was significantly greater than in the three comparator groups (2020, 2019, and viral lower respiratory tract illness groups).” (Daugherty et. al. 2021)……….
Read More: Link